Please Wait...

Human Amyloid Imaging (HAI) Annual Conference

January 16, 2019 - 1:00am (EST) to January 18, 2019 - 1:00am (EST)

Bioclinica's scientific and medical imaging experts continue to explore ways to improve longitudinal signal detection in amyloid and tau PET in the context of global, multi-center clinical trials.

HAI attendees are invited to view four poster sessions where our team will share findings in assessing the impact of BACE inhibition on amyloid load in recent clinical trials, as well as early experience with application of tracer-specific cutoffs to centiloids and optimization of longitudinal tau PET analysis.

  • Subject-specific site of maximum uptake is most sensitive to longitudinal change in 18F-AV1451 PET data
    Authors: David Scott, PhD; Kate Adamczuk, PhD; Beth Gorman, BS, CNMT; Maureen Runkle, BS, CNMT; Joyce Suhy, PhD
    Presenter: David Scott, PhD
  • Centiloid scale in practice: effect of different SUVR reference regions and comparison of Centiloid cut-offs
    Authors: Kate Adamczuk, PhD; Mehul Sampat, PhD; Maureen Runkle, BS, CNMT; Beth Gorman, BS, CNMT; Joyce Suhy, PhD; David Scott, PhD
    Presenter: Kate Adamczuk, PhD
  • PET analysis of verubecestat on amyloid load in mild-to-moderate Alzheimer's disease patients (EPOCH trial)
    Authors: Cyrille Sur, PhD; Kate Adamczuk, PhD; Mehul Sampat, PhD; James Kost; PhD; David Scott, PhD; Joyce Suhy, PhD; Michael Egan, MD
    Presenter: Cyrille Sur, PhD
  • Effect of verubecestat on amyloid load in prodromal Alzheimer's disease patients: Results from the PhIII APECS trial
    Authors: Cyrille Sur, PhD; James Kost, PhD; Kate Adamczuk, PhD; David Scott, PhD; Joyce Suhy, PhD; Michael Egan, MD
    Presenter: Cyrille Sur, PhD

If you're attending HAI and would like to meet with Bioclinica's onsite team, please email,,, or

Visit event website



Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @endpts: #FDA revises draft guidance on #raredisease drug R&D by @ZacharyBrennan via @RAPSorg
Bioclinica (8 hours ago)
RT @PrimeVigilance: News and Press Release - Source @EMA_News now available monthly meeting highlights from #Pharmacovigilance #RiskAssessm…
Bioclinica (8 hours ago)
RT @FDA_Drug_Info: New #FDA Draft Guidance for Industry on Rare Diseases – Common Issues in Drug Development: http…
Bioclinica (8 hours ago)
Looking to exercise DDDM in clinical trials? Get tips on obtaining, distilling and presenting data in our new white…
Bioclinica (10 hours ago)
Is your clinical study supply chain management solution increasing the risk of stock out? Ehsan Ramezani gives pers…
Bioclinica (Yesterday)
Bioclinica's Kate Adamczuk is presenting at #HAI2019 today! Details on this and other scientific findings at HAI…
Bioclinica (Yesterday)

Latest Blogs:

Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner